| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, July 10 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN), today said that he believes that stem cell cord blood banking is a "huge business opportunity for hospitals worldwide." The Bio-Matrix CEO stated that hospitals throughout the world are now eagerly starting their own stem cell cord blood banks. "Hospitals from the U.S. to India are naturally interested in providing cord blood banking facilities to their patients and the overall awareness of this stem cell storage banking concept is catching on fast." Bio-Matrix recently announced a new company marketing program aimed specifically at hospitals and research centers interested in using its 15,000 square foot stem cell storage bank facility in San Diego.
According to Koos, "Companies like Bio-Matrix are making use of a ready-made patient customer base by linking up with hospitals, medical institutes, research institutions and biotechnology companies to assist in stem cell research and treatments. For hospitals, this kind of marketing partnership is synergistic at its roots because hospitals would promote cord blood storage banks leading to additional revenue from every newborn baby delivered. Many hospitals are starting this kind of cord blood business as part of their gynecological services because it's a natural extension of the basic service hospitals provide already and is a cash-rich add on as well."
Koos said that BMSN intends to expand its own marketing program to include stem cell therapy centers. "We are looking for strategic alliances with hospitals and research centers on a global level. The Company believes it can assist these medical institutions in better educating parents about cord blood banking. We are also in the midst of identifying regional and local partners whom we can work with."
About Bio-Matrix Scientific Group
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
'/>"/>
| SOURCE Bio-Matrix Scientific Group Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
3. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. CDC Awards NATT Funding to Improve Blood Clot Awareness
6. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
7. Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis
8. Blood Donations in U.S. Testing Positive for Chagas Disease
9. One of Nations Oldest Blood Services Providers Turns to Sysmex America
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |